family with sequence similarity 217 member BGenealiases: C20orf177 · dJ551D2.5
Q-omics provides the consensus-scored FAM217B profile across patient tissues and cancer cell-line models. FAM217B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FAM217B is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, FAM217B RNA expression shows 20,331 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where FAM217B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM217B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM217B survival associations across molecular data types. FAM217B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM217B RNA expression–survival associations across cancer types. High FAM217B expression shows unfavorable associations in UVM, LIHC, KICH and BLCA, but favorable associations in KIRC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for FAM217B RNA expression.
This table summarizes FAM217B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM217B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM217B shows higher tumor expression in HNSC, LIHC, KIRP, KIRC, BLCA and LUSC. The HNSC box plot shows higher FAM217B RNA expression in tumor versus normal tissue (log2 FC = +0.668, t-test p < 0.001).
This table shows molecular features associated with FAM217B in patient tissues and cancer cell lines. In patient samples, FAM217B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM217B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
